Nohla Therapeutics Raises $45M, Reaches $100M Total as Dilanu**bicel Advances Toward FDA Approval

Nohla Therapeutics raised $45 million in equity, bringing its total funding to $100 million as it advances dilanubicel, a cord‑blood–derived stem cell leukemia treatment, toward FDA approval. The Fred Hutch spinout has doubled headcount to 43 and moved to a new Seattle headquarters while attracting investors including Fidelity and Celgene.

No comments yet.